|Values are valid only on day of printing.|
Acute myeloid leukemia (AML) with mutated CCAAT/enhancer-binding protein alpha gene (CEBPA) is a diagnostic category in the current WHO classification of hematopoietic neoplasms.(1) In addition, CEBPA mutation on both alleles (so-called double mutation status) is considered a good prognostic feature in adults with newly diagnosed AML who have a normal karyotype or do not contain an alternate diagnostic genetic abnormality.(2,3) Thus, evaluation for CEBPA mutations is necessary for accurate diagnosis in the current classification system and contributes prognostic information for a large group of AML patients.
Initial evaluation of acute myeloid leukemia, both for assigning an appropriate diagnostic subclassification and as an aid for determining prognosis.
The results will be given as positive or negative for CEBPA mutation and, if positive, the mutation will be described and single or double mutation status will be indicated.
The assay is performed using Sanger sequencing, which has a sensitivity of 20%. This means that 20% or more of the DNA in the sample must be mutated to be detected. Consequently, this test is intended for use at the time of diagnosis, and not for disease monitoring.
An interpretive report will be provided
1. Swerdlow S, Campo E, Harris N, et al: WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Press 2008; pp 109-145
2. Wouters B, Lowenberg B, Erpelinck-Verschueren C, et al: Double CEBPA mutations, but not single CEBPA mutations, define a subset of acute myeloid leukemia with a distinctive expression profile that is uniquely associated with a favorable outcome. Blood 2009;113:3088-3091
3. Pabst T, Eyholzer M, Fos J, et al: Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009;100:1343-1346